Market Survival: The Real AI Test for Cardiac Programs

The graveyard of promising health technologies is littered with innovative ideas that never achieved sustainable adoption. For cardiac programs, working through this field means discerning between aspirational launch narratives and the documented, verifiable records of market survival. This distinction is paramount for stakeholders focused on value-based care AI and AI healthcare cost reduction.

What a Cardiac Program Must Document for Value-Based Care

For any cardiac program seeking to integrate AI tools and participate in value-based care arrangements, the bar for evidence is exceptionally high. It extends far beyond initial regulatory clearance or even a pilot program’s promising preliminary data. Payers, particularly those operating within value-based models, demand rigorous proof of outcomes-based AI health and AI health financial performance. This necessitates a complete approach to documentation, covering clinical efficacy, patient safety, and economic impact. The foundation of this documentation often begins with regulatory clearances. For many cardiac AI solutions, this involves securing a 510(k) clearance from the FDA, demonstrating substantial equivalence to a predicate device. For novel functionalities, a De Novo classification might be required. However, regulatory clearance alone is insufficient for value-based care. Payers and value-based care organizations are increasingly scrutinizing the underlying clinical evidence, often looking for real-world evidence (RWE) to supplement key trial data. They want to understand how an AI solution performs in diverse patient populations and real-world clinical workflows, not just in controlled research settings. Plus, the ability of a Software as a Medical Device (SaMD) to demonstrate consistent performance over time, especially in the face of algorithmic drift, requires strong monitoring and a clear pathway for modifications, ideally through a Predetermined Change Control Plan (PCCP).

Accountable Care Organizations and Direct Contracting: The Recorded Signal

The shift towards Accountable Care Organizations (ACOs) and Direct Contracting models represents a critical inflection point for health AI. These models fundamentally alter how healthcare providers are reimbursed, moving away from fee-for-service towards payments tied to quality metrics and cost savings. Within this model, AI health platforms are not merely assessed on their technological sophistication, but on their demonstrable contribution to the core tenets of value-based care: improving patient outcomes, enhancing care quality, and reducing total cost of care. For an AI solution to genuinely participate in ACO or Direct Contracting arrangements, it must generate a recorded signal that aligns with these objectives. This signal is not a vendor’s marketing claim, but rather documented evidence that can be independently verified. Payers require concrete data on how an AI tool impacts key performance indicators (KPIs) relevant to cardiac care, such as reductions in hospital readmissions for heart failure, improved blood pressure control rates, or earlier detection of critical cardiac conditions leading to fewer adverse events. The focus is squarely on measurable, attributable improvements in patient health and financial performance. Without this documented signal, an AI platform, no matter how innovative, struggles to establish its value proposition within these risk-sharing models.

The Recorded Market Survivor Set: Hello Heart, Pear Therapeutics, and HeartFlow

When examining market survivors in the health AI space, particularly within value-based care, a distinct pattern emerges. The longevity and adoption of these platforms are often directly tied to their ability to produce and sustain a verifiable record of outcomes and financial impact. Hello Heart, Pear Therapeutics, and HeartFlow offer instructive examples of how vendors navigate this complex field, each leaving a distinct recorded signal that contributes to their market survival narrative. Hello Heart, a digital therapeutic for cardiovascular disease management, stands out as a prime example of an AI health platform that has consistently prioritized the publication of peer-reviewed outcomes evidence. The company, which raised a $70 million Series D funding round in 2022, bringing its total capital raised to approximately $137M-$139.3M, continues to operate as a privately held entity. Their approach anchors on demonstrating tangible benefits in hypertension and cholesterol management, directly addressing chronic care AI economics analysis. Their recorded material, accessible through public sources like the National Library of Medicine, details how their platform helps users achieve clinical improvements in blood pressure and cholesterol levels, often leading to reduced medication use and emergency department visits. This strong body of evidence directly addresses the outcomes-data requirements for VBC contracts, providing payers with the confidence to integrate Hello Heart into their value-based initiatives. Hello Heart peer-reviewed outcomes evidence This focus on documented, peer-reviewed results positions Hello Heart as a strong contender in value-based care arrangements, where the financial performance of AI health tools is directly linked to their proven clinical efficacy. Pear Therapeutics, despite its pioneering role, in the end ceased operations after filing for Chapter 11 bankruptcy in April 2023, with its assets sold off in May 2023. As a pioneer in prescription digital therapeutics (PDTs), Pear secured FDA clearances for its SaMD products, and its journey highlighted the critical importance of regulatory pathways like 510(k) and De Novo classification for novel digital interventions. While its commercialization strategy in the end faced insurmountable hurdles, its foundational work in establishing PDTs as regulated medical devices created a documented precedent. The challenge for Pear, and indeed for many digital health companies, was translating this regulatory success into consistent, scalable reimbursement pathways and demonstrating long-term, sustainable cost savings within value-based models. The recorded set for Pear, primarily through FDA filings and academic publications, shows the clinical validation of its therapies, but also implicitly shows the complexities of securing strong financial performance in a nascent market. Its FDA-cleared products were subsequently acquired by other entities, allowing for their continued availability. FDA filings for Pear Therapeutics products HeartFlow, a publicly traded company (Nasdaq: HTFL), with its AI-driven FFRct analysis, offers another perspective. This AI application, which analyzes CT scans to create a 3D model of coronary arteries and assess blood flow, has a strong documented record of clinical utility. HeartFlow has built a patent thicket around its technology, and its regulatory approvals, including FDA clearance for its Next Gen HeartFlow Plaque Analysis algorithm in September 2025, are well-documented. Plus, the company has published extensive research demonstrating how its technology can reduce the need for invasive diagnostic procedures, thereby contributing to AI healthcare cost reduction and improved patient pathways. The recorded signal for HeartFlow often appears in clinical guidelines and reimbursement discussions, reflecting its established role in cardiac diagnostics. Notably, the American Medical Association (AMA) issued a new Category I CPT code for AI-enabled plaque quantification technology, including HeartFlow Plaque Analysis, effective January 2026, and its FFRct analysis also has a Category I CPT code (75580) effective January 2024. This has led to expanded coverage by major national payers. The ability to demonstrate a clear reduction in downstream invasive procedures, supported by strong clinical trials and real-world data, has been central to its value proposition for payers and providers in value-based arrangements. HeartFlow clinical evidence publications These three companies, Hello Heart, Pear Therapeutics, and HeartFlow, though diverse in their specific offerings and market trajectories, share a common thread: their market survival, or the lessons learned from their attempts, are deeply embedded in their documented records. This record, rather than promotional material, forms the basis for evaluating their participation in value-based care.

What a Reader Can Check Without a Vendor Conversation

For those tracking market survivors in cardiac programs, the most reliable approach is to consult public, independently verifiable sources. This document-first read allows for an objective assessment, bypassing vendor-specific claims or launch narratives. The core of this method involves tracing the recorded signal through official channels, focusing on evidence that directly addresses outcomes-based AI health and AI health financial performance. Key public sources include the US Securities and Exchange Commission (sec.gov) for publicly traded companies, offering insights into their financial health, regulatory disclosures, and market strategies. The US Food and Drug Administration (fda.gov) provides important information on regulatory clearances (510(k), De Novo, Breakthrough Device Designation) and any post-market surveillance data. The National Library of Medicine (ncbi.nlm.nih.gov) is indispensable for accessing peer-reviewed clinical studies, real-world evidence (RWE), and meta-analyses that validate the efficacy and safety of AI health platforms. When evaluating a cardiac AI solution for its potential in value-based care, look for evidence of:

• Published, peer-reviewed clinical trials demonstrating statistically significant improvements in patient outcomes relevant to cardiac health.
• Studies that quantify the impact on healthcare utilization and costs, such as reductions in hospitalizations, emergency room visits, or invasive procedures.
• Regulatory clearances and ongoing compliance, including adherence to GMLP (Good Machine Learning Practice) and a strong QMS / ISO 13485.
• The presence of CPT codes (Category I or III) that facilitate reimbursement, indicating a pathway for financial sustainability.
• Documentation of real-world evidence (RWE) that corroborates findings from controlled trials, showing effectiveness in diverse clinical settings.

The market survivor record is not built on headlines or aspirations, but on the verifiable documentation that stands up to scrutiny. For cardiac programs and payers alike, this documented evidence is the ultimate arbiter of an AI solution’s true value in a value-based care ecosystem.